CTOs on the Move

Denali Therapeutics

www.denalitherapeutics.com

 
Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Denali Therapeutics raised $217M on 05/14/2015

Similar Companies

Orna Therapeutics

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna`s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.

Enzyvant

Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.

IO Biotech

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

Akaza Research

Akaza Research is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celsius Therapeutics

Celsius Therapeutics is a community of scientists, technologists, clinicians and drug hunters leveraging single-cell RNA sequencing and genomic analysis to develop life-changing medicines. Our common goal is to markedly improve human health by integrating data, experience and insight. Located in Cambridge, Mass., our environment is rigorous, fast-paced and collaborative, bringing together passionate individuals who are making an impact. We inspire creativity and discovery by embracing an open culture that fosters innovation, teamwork and excellence. We are committed to attracting and retaining the best talent, and we believe that our growth and success will be driven by those who are inspired by our mission and share our values. If you`re curious, collaborative and relentless about making a difference in the lives of patients, join us!